China News Service, Beijing, September 2 (Reporter Li Yanan) Currently, the number of cardiovascular disease patients in China has reached 290 million. Cardiovascular disease deaths account for more than 40% of the residents’ disease deaths, higher than tumors and other diseases.

Experts emphasize that long-term management of chronic diseases such as cardiovascular and cerebrovascular diseases is important, and patient compliance is very important, and good medication habits can help standardize treatment.

  According to the "China Cardiovascular Disease Report 2018" issued by the National Cardiovascular Disease Center in 2019, China currently has 290 million patients with cardiovascular diseases, 13 million strokes, 11 million coronary heart diseases, and more than 200 million people with hypertension. The prevalence of hypertension among residents aged 18 and over is 25.2%, and it is showing an upward trend.

  Fan Dongsheng, director of the Department of Neurology, Peking University Third Hospital, pointed out that there are primary prevention and secondary prevention for cardiovascular and cerebrovascular diseases. The target population for primary prevention is people who already have one or more risk factors for cardiovascular and cerebrovascular diseases. These people not only need to be corrected Poor lifestyles often require rational use of drugs to minimize the risk of serious cardiovascular and cerebrovascular diseases in the future.

  The target population of secondary prevention is patients who have already suffered from cardiovascular and cerebrovascular diseases. The main goal is to prevent the further development of the disease, especially to prevent the disease from recurring acute attack.

There are currently a series of treatment measures for secondary prevention, including long-term use of related drugs. For these patients, the control of existing risk factors is very important. Blood pressure, blood cholesterol, blood sugar and weight should be maintained normal and bad lifestyle should be corrected. .

  "Cardio-cerebrovascular diseases are chronic diseases. Chronic disease management is lifelong management. It requires long-term medication. This also means that the efficacy of the drugs must be safe and reliable, and the price must not be too expensive." Professor Dongsheng Fan said, including the expansion of procurement Since the implementation of measures such as the environmental protection measures, the price of the original research drug has been greatly reduced while ensuring the quality, which is very beneficial to improve patient compliance. For example, the price of a bottle of mineral water per day can ensure better prevention quality.

  From the first batch of "4+7" pilot projects to the second batch of 25 provinces and cities expansion, and the third batch of national mass procurement recently started gradually, the centralized mass procurement of drugs is becoming normal, and the scope of centralized procurement and drugs The variety is also increasing.

  After the expansion policy was implemented in Beijing, the commonly used drugs for cardiovascular diseases, Ambonol (irbesartan hydrochlorothiazide tablets) and the cornerstone of antiplatelet therapy Polivix (clopidogrel bisulfate tablets), were used as examples for hypertension and acute. The price of the treatment of myocardial infarction, angina, stroke and peripheral artery disease has been reduced from the original 25.7 yuan/box and 91.7 yuan/box to 9.8 yuan/box and 24.8 yuan/box, respectively. At the same time, medical insurance can be reimbursed up to 90%.

  Fan Dongsheng added that in the management of chronic diseases, patient compliance is a very important part. For chronic diseases, prevention is more important than treatment. Effective prevention can reduce the occurrence of malignant events. Therefore, it is very important to strengthen patient health education. necessary.

However, due to the high price of medicines, it is difficult for some patients to persist, so price factors must also be considered.

After the price of some original research drugs drops, it can effectively reduce the economic pressure of patients during use, so that they can better follow the doctor's advice and do a good job in the prevention and control of chronic diseases.